SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that senior management will present at upcoming investor conferences.
Leerink Partners 7th Annual Global Healthcare Conference
Thursday, February 15, 2018 at 9:30 a.m. Eastern Time in New York.
RBC Capital Markets 2018 Global Healthcare Conference
Wednesday, February 21, 2018 at 4:05 p.m. Eastern Time in New York.
Cowen & Company 38th Annual Health Care Conference
Monday, March 12, 2018 at 12:00 p.m. Eastern Time in Boston.
A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of each presentation will be available on the company website for 30 days.
About Immune Design
Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex® and GLAAS®. Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
Source: Immune Design Corp.